{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:12Z","timestamp":1783075932593,"version":"3.54.6"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,9,9]],"date-time":"2008-09-09T00:00:00Z","timestamp":1220918400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s00228-008-0556-9","type":"journal-article","created":{"date-parts":[[2008,9,8]],"date-time":"2008-09-08T01:45:47Z","timestamp":1220838347000},"page":"89-95","source":"Crossref","is-referenced-by-count":15,"title":["Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib"],"prefix":"10.1007","volume":"65","author":[{"given":"Ville V.","family":"Hynninen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus T.","family":"Olkkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pertti J.","family":"Neuvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Laine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,9,9]]},"reference":[{"key":"556_CR1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/0091270003251122","volume":"43","author":"NG Agrawal","year":"2003","unstructured":"Agrawal NG, Porras AG, Matthews CZ, Rose MJ, Woolf EJ, Musser BJ, Dynder AL, Mazina KE, Lasseter KC, Hunt TL, Schwartz JI, McCrea JB, Gottesdiener KM (2003) Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 43:268\u2013276","journal-title":"J Clin Pharmacol"},{"key":"556_CR2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1124\/dmd.31.2.224","volume":"31","author":"AD Rodrigues","year":"2003","unstructured":"Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, Gottesdiener KM, Larson PJ, Lasseter KC, Agrawal NG (2003) Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos 31:224\u2013232","journal-title":"Drug Metab Dispos"},{"key":"556_CR3","first-page":"813","volume":"29","author":"K Kassahun","year":"2001","unstructured":"Kassahun K, McIntosh IS, Shou M, Walsh DJ, Rodeheffer C, Slaughter DE, Geer LA, Halpin RA, Agrawal N, Rodrigues AD (2001) Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 29:813\u2013820","journal-title":"Drug Metab Dispos"},{"key":"556_CR4","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","volume":"28","author":"T Niwa","year":"2005","unstructured":"Niwa T, Shiraga T, Takagi A (2005) Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28:1805\u20131808","journal-title":"Biol Pharm Bull"},{"key":"556_CR5","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1248\/bpb.28.1813","volume":"28","author":"T Niwa","year":"2005","unstructured":"Niwa T, Inoue-Yamamoto S, Shiraga T, Takagi A (2005) Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol Pharm Bull 28:1813\u20131816","journal-title":"Biol Pharm Bull"},{"key":"556_CR6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.30.3.314","volume":"30","author":"W Zhang","year":"2002","unstructured":"Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM (2002) Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 30:314\u2013318","journal-title":"Drug Metab Dispos"},{"key":"556_CR7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/clpt.1992.78","volume":"51","author":"RA O\u2019Reilly","year":"1992","unstructured":"O\u2019Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, Eddy AC, Trager WF (1992) Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 51:656\u2013667","journal-title":"Clin Pharmacol Ther"},{"key":"556_CR8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/bmj.314.7077.349a","volume":"314","author":"S Ariyaratnam","year":"1997","unstructured":"Ariyaratnam S, Thakker NS, Sloan P, Thornhill MH (1997) Potentiation of warfarin anticoagulant activity by miconazole oral gel. BMJ 314:349","journal-title":"BMJ"},{"key":"556_CR9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.bdj.4811224","volume":"196","author":"MN Pemberton","year":"2004","unstructured":"Pemberton MN, Oliver RJ, Theaker ED (2004) Miconazole oral gel and drug interactions. Br Dent J 196:529\u2013531","journal-title":"Br Dent J"},{"key":"556_CR10","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1055\/s-0037-1613916","volume":"83","author":"M Silingardi","year":"2000","unstructured":"Silingardi M, Ghirarduzzi A, Tincani E, Iorio A, Iori I (2000) Miconazole oral gel potentiates warfarin anticoagulant activity. Thromb Haemost 83:794\u2013795","journal-title":"Thromb Haemost"},{"key":"556_CR11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clpt.2005.12.305","volume":"79","author":"TI Saari","year":"2006","unstructured":"Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT (2006) Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 79:362\u2013370","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"556_CR12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2125.2003.01995.x","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Kleinermans D, Nichols D (2003) Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 56(Suppl 1):24\u201329","journal-title":"Br J Clin Pharmacol"},{"key":"556_CR13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H (2006) Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45:649\u2013663","journal-title":"Clin Pharmacokinet"},{"key":"556_CR14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF02265118","volume":"45","author":"C Brideau","year":"1996","unstructured":"Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, Chan CC (1996) A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45:68\u201374","journal-title":"Inflamm Res"},{"key":"556_CR15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0378-4347(99)00565-4","volume":"748","author":"CM Chavez-Eng","year":"2000","unstructured":"Chavez-Eng CM, Constanzer ML, Matuszewski BK (2000) Determination of rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. J Chromatogr B Biomed Sci Appl 748:31\u201339","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"556_CR16","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0731-7085(98)00004-1","volume":"17","author":"R Gage","year":"1998","unstructured":"Gage R, Stopher DA (1998) A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal 17:1449\u20131453","journal-title":"J Pharm Biomed Anal"},{"key":"556_CR17","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1128\/AAC.47.7.2348-2350.2003","volume":"47","author":"GJ Pennick","year":"2003","unstructured":"Pennick GJ, Clark M, Sutton DA, Rinaldi MG (2003) Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 47:2348\u20132350","journal-title":"Antimicrob Agents Chemother"},{"key":"556_CR18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0378-4347(96)00245-9","volume":"687","author":"D Compas","year":"1996","unstructured":"Compas D, Touw DJ, de Goede PN (1996) Rapid method for the analysis of itraconazole and hydroxyitraconazole in serum by high-performance liquid chromatography. J Chromatogr B Biomed Appl 687:453\u2013456","journal-title":"J Chromatogr B Biomed Appl"},{"key":"556_CR19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chroma.2006.08.093","volume":"1134","author":"PH Roberts","year":"2006","unstructured":"Roberts PH, Bersuder P (2006) Analysis of OSPAR priority pharmaceuticals using high-performance liquid chromatography-electrospray ionisation tandem mass spectrometry. J Chromatogr 1134:143\u2013150","journal-title":"J Chromatogr"},{"key":"556_CR20","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.clpt.2006.07.008","volume":"80","author":"TI Saari","year":"2006","unstructured":"Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT (2006) Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther 80:502\u2013508","journal-title":"Clin Pharmacol Ther"},{"key":"556_CR21","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1177\/0091270004268129","volume":"44","author":"NG Agrawal","year":"2004","unstructured":"Agrawal NG, Matthews CZ, Mazenko RS, Woolf EJ, Porras AG, Chen X, Miller JL, Michiels N, Wehling M, Schultz A, Gottlieb AB, Kraft WK, Greenberg HE, Waldman SA, Curtis SP, Gottesdiener KM (2004) The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. J Clin Pharmacol 44:1125\u20131131","journal-title":"J Clin Pharmacol"},{"key":"556_CR22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0091270003253703","volume":"43","author":"A Dallob","year":"2003","unstructured":"Dallob A, Hawkey CJ, Greenberg H, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K (2003) Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol 43:573\u2013585","journal-title":"J Clin Pharmacol"},{"key":"556_CR23","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1161\/CIRCULATIONAHA.105.602425","volume":"113","author":"F Andersohn","year":"2006","unstructured":"Andersohn F, Suissa S, Garbe E (2006) Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 113:1950\u20131957","journal-title":"Circulation"},{"key":"556_CR24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0149-2918(04)90007-0","volume":"26","author":"SP Curtis","year":"2004","unstructured":"Curtis SP, Ng J, Yu Q, Shingo S, Bergman G, McCormick CL, Reicin AS (2004) Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther. 26:70\u201383","journal-title":"Clin Ther."}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0556-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-008-0556-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0556-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:51:53Z","timestamp":1558702313000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-008-0556-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,9]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["556"],"URL":"https:\/\/doi.org\/10.1007\/s00228-008-0556-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,9]]}}}